Myriad Value Chain Analysis
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Dive Deeper Into the Activities Behind the Analysis
This Myriad Value Chain Analysis helps you understand how Myriad creates value across support and primary activities in a clear, structured format. This page already includes a real preview of the actual analysis, so you can review the content and style before buying. Purchase the full version to get the complete ready-to-use report.
Support Activities
Firm Infrastructure
In fiscal 2025, Myriad Genetics, Inc. relied on CLIA-controlled labs, strong governance, and payer management because every test sits between medicine and reimbursement. With 2025 revenue of about $810 million, firm infrastructure is a scale issue, not a back-office detail. That control helps Myriad Genetics, Inc. protect clinical trust while pushing tests into broader use.
Human Resource Management
Myriad Genetics, Inc. relies on scientists, lab staff, genetic counselors, bioinformaticians, and specialty sales teams to keep test quality high and physicians well trained. In FY2025, hiring and retention matter because each new assay in oncology, women's health, and pharmacogenomics depends on skilled people who can validate, explain, and scale it. This talent base also supports faster launches and steadier revenue growth.
Technology Development
Myriad Genetics, Inc. uses technology development to build assay design, clinical validation, and data-interpretation software that turn genomic evidence into reimbursable tests. In 2025, Myriad Genetics, Inc. reported full-year revenue of about $807 million, showing how test innovation supports commercialization at scale. Its strategy matters most in oncology, women's health, and mental health, where faster validation can improve payer coverage and differentiation.
Procurement
Myriad Genetics, Inc. procures lab instruments, reagents, sequencing and assay consumables, software tools, and reference materials to keep its test flow steady. Tight sourcing helps cut unit cost, protect throughput, and reduce delays when sample quality and turnaround time drive revenue and client trust.
In a diagnostics business, even small supply gaps can slow runs and raise repeat-test risk, so procurement is part cost control and part service quality control.
Myriad Genetics Keeps the Lab Engine Running in FY2025
In FY2025, Myriad Genetics, Inc. kept support work tight: sourcing lab inputs, maintaining CLIA lab controls, and funding science and software that protect test quality. With about $807 million to $810 million in full-year revenue, small delays in reagents, instruments, or data tools can hit throughput and reimbursement fast. People, systems, and procurement are not overhead here; they keep tests moving and physicians trusting the result.
| FY2025 support focus | Why it matters |
|---|---|
| CLIA labs | Quality and compliance |
| Procurement | Protects throughput |
| Technology | Supports validation |
What is included in the product
Detailed Word Document
Editable Excel File
Primary Activities
Inbound Logistics
Myriad Genetics, Inc. inbound logistics starts with physician-ordered specimens, collection kits, and shipping materials moving through a controlled intake flow. In FY2025, the key operating risk was still sample quality: bad or mislabeled specimens can delay testing, raise rework costs, and weaken reimbursement. Tight chain-of-custody checks protect turnaround time and help keep every billable sample usable.
Operations
Myriad Genetics, Inc. uses accessioning, sequencing or assay processing, bioinformatic analysis, variant interpretation, and report generation to turn a biological sample into a clinical result. This is the main value-creation step in molecular diagnostics, where speed and accuracy drive uptake by doctors and payers. The workflow also supports Myriad Genetics, Inc. test menu across hereditary cancer and women's health.
Outbound Logistics
Myriad Genetics, Inc. uses digital reports and integrated workflows to move results back to clinicians and health systems fast, which matters because a test only creates value when the care team sees it in time to act. In FY2025, that speed supports adoption by cutting manual handoffs and helping results land inside existing clinical systems. Faster, accurate delivery also helps reduce repeat calls and delays in follow-up care.
Marketing and Sales
In 2025, Myriad Genetics, Inc. relies on specialty sales teams, medical education, evidence generation, and payer talks to drive test use. The goal is to win physician trust in oncology, women's health, and pharmacogenomics while also supporting reimbursement and stronger test utilization across care settings.
Service
Myriad Genetics, Inc. backs its tests with genetic counseling, provider education, result clarification, and reimbursement help, so clients can act on complex genomic findings faster. This service layer matters because clear post-sale support can lift repeat use, improve satisfaction, and support referral flow in a high-touch diagnostics market.
Myriad Genetics Turns Genomic Tests Into Faster Care
In FY2025, Myriad Genetics, Inc. creates value by turning physician-ordered samples into fast, accurate genomic results through lab processing, bioinformatics, and variant review. That speed matters because each delay can slow care and hurt reimbursement.
Its delivery model uses digital reporting, clinician integration, sales education, and payer support to lift test use across oncology, women's health, and pharmacogenomics. The service layer also helps drive repeat orders and smoother follow-up care.
| Primary activity | FY2025 value point |
|---|---|
| Operations | Sample to report workflow |
| Outbound logistics | Fast digital result delivery |
| Marketing and sales | Physician and payer support |
| Service | Genetic counseling and help |
Get Your Copy
Myriad Reference Sources
The preview below is the same Myriad Value Chain Analysis document you'll receive after purchase – no hidden changes, no surprises. You're viewing a real excerpt from the full report, so the structure, content, and quality reflect the final file. Once purchased, the complete version is unlocked immediately for download.
Frequently Asked Questions
As of March 2026, Myriad Genetics, Inc. creates value by turning 3 clinical goals into actionable genetic reports: risk assessment, treatment-response prediction, and progression or recurrence assessment. Its model spans 3 focus areas-oncology, women's health, and pharmacogenomics for mental health-which lets the same testing infrastructure serve multiple clinical settings and revenue streams.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.